



Press release from Emotra AB (publ)

Göteborg, May 9, 2018

Communiqué from the Annual General Meeting of EMOTRA AB (publ)

The Annual General Meeting of EMOTRA AB (publ) was held today, May 9, 2018. The resolutions, summarised below, were all adopted with the necessary majority.

Net income appropriation

The AGM approved the Board's proposal for allocation of the Company's loss as presented in the annual report.

Furthermore, the Board recommends no dividend be paid for the financial year 2017. The AGM also granted the Board of Directors and the CEO discharge for the financial year 2017.

Determination of the number of board members and deputy members, as well as the number of accountants and deputy accountants; determination of the fees to be paid to the board members and accountant

The AGM decided that the Board shall be composed of four regular members and no deputy members and set the annual compensation for the Board to 125,000 SEK, whereof 80,000 SEK for the chairperson and 45,000 SEK for the external/independent regular board member. Furthermore, the AGM decided that an auditor and a deputy auditor shall be appointed, and that they shall be compensated in line with usual charges and upon presentation of approved invoice.

Election of Board of Directors and accountant

The AGM decided that Margit Ferm, Claes Holmberg, Jan Pilebjer* and Lars-Håkan Thorell shall be reelected as regular board members. Furthermore, the AGM passed a resolution to renew the appointment of Thomas Nilsson as the Company's auditor and Marcus Hellsten as deputy auditor until next year's Annual General Meeting.

**independent board member, according to the regulatory framework of AktieTorget*

Resolution on granting the Board authority to decide on a new rights issue

The AGM resolved to authorise the Board to issue new shares, within the framework of the Swedish articles of association, on one or more occasions up until the next AGM, without deviation from the shareholders' preferential rights.

The number of shares issued under the authorisation shall correspond to an amount of 24,000,000 SEK, or a maximum of 2,500,000 euro (total issue proceeds).

The shares will be issued at a market-equivalent price, minus a market-rate issue rebate, when appropriate, and payment can, in addition to cash, be made in kind or as otherwise conditioned.

The goal of any new share issue that is decided based on the granted authority shall be to reinforce the Company's working capital to finance the market launch of the Company's method EDOR®.

The meeting also resolved to authorise the Board, or a person appointed by the Board, to make any minor adjustments to the AGM resolution that may prove necessary when registering the decision.

Emotra AB (publ)
THE BOARD OF DIRECTORS

For further information, please contact: Claes Holmberg, CEO, telephone: +46 708 25 45 47, E-mail: claes@emotra.se

EMOTRA AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

EMOTRA AB (publ), Göteborgsvägen 88, SE-433 63 Sävedalen, Sweden
Tel: +46 708 25 45 47, www.emotra.se

EMotra